According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that:
- manufacturing for Inovio’s CELLECTRA device was deficient;
- accordingly, Inovio was unlikely to submit the INO-3107 Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) by the second half of 2024;
- Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review;
- accordingly, INO-3107’s overall regulatory and commercial prospects were overstated; and
- as a result, defendants’ public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
